Assessing the feasibility of Nipah vaccine efficacy trials based on previous outbreaks in Bangladesh

Birgit Nikolay, Marc Lipsitch, Mahmudur Rahman, Stephen P. Luby, Henrik Salje, Emily S. Gurley, Simon Cauchemez
doi: https://doi.org/10.1101/2020.12.06.20244871

Article Information

doi 
https://doi.org/10.1101/2020.12.06.20244871
History 
  • December 8, 2020.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Author Information

  1. Birgit Nikolay1,
  2. Marc Lipsitch2,
  3. Mahmudur Rahman3,
  4. Stephen P. Luby4,
  5. Henrik Salje*,1,5,†,
  6. Emily S. Gurley*,3,6 and
  7. Simon Cauchemez*,1
  1. 1Mathematical Modelling of Infectious Diseases Unit, Institut Pasteur, UMR2000, CNRS, 75015 Paris, France
  2. 2Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA
  3. 3Consultant
  4. 4Infectious Diseases and Geographic Medicine Division, Stanford University, Stanford, California, USA
  5. 5Cambridge Infectious Diseases, University of Cambridge, Cambridge, UK
  6. 6Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
  1. ↵†Corresponding author: Henrik Salje; Email: hs743{at}cam.ac.uk
Back to top
Posted December 08, 2020.
Download PDF

Supplementary Material

Data/Code
Email
Assessing the feasibility of Nipah vaccine efficacy trials based on previous outbreaks in Bangladesh
Birgit Nikolay, Marc Lipsitch, Mahmudur Rahman, Stephen P. Luby, Henrik Salje, Emily S. Gurley, Simon Cauchemez
medRxiv 2020.12.06.20244871; doi: https://doi.org/10.1101/2020.12.06.20244871
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area